Updated Jul 16, 2026 · Last SEC filing 2026-06-10
Vir Biotechnology, Inc. (VIR) has filed 11 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-10. 3 Form 8-K material event filings were reported by VIR in the last 90 days. 4 Form 144 notices of proposed sale were filed for VIR stock. InsiderAlpha tracks every VIR SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001706431 |
| Form 4 filings (90d) | 11 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 4 |
| Latest Form 4 filing | 2026-06-10 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Coughlin Timothy | Director | A — Grant or award | 8.0K | $0.00 | — | SEC | |
| Coughlin Timothy | Director | A — Grant or award | 8.0K | $0.00 | — | SEC | |
| Napolitano Janet | Director | S — Open-market sale | 3.2K | $9.45 | $30K | SEC | |
| Sabatini Brent | SVP, Chief Accounting Officer | S — Open-market sale | 379 | $9.45 | $4K | SEC | |
| Hatfield Jeffrey S. | Director | A — Grant or award | 8.0K | $0.00 | — | SEC | |
| Sigal Charles Elliott | Director | A — Grant or award | 8.0K | $0.00 | — | SEC | |
| MORE ROBERT J | Director | A — Grant or award | 8.0K | $0.00 | — | SEC | |
| Farid Ramy | Director | A — Grant or award | 8.0K | $0.00 | — | SEC | |
| BISCHOFBERGER NORBERT W | Director | A — Grant or award | 8.0K | $0.00 | — | SEC | |
| Napolitano Janet | Director | A — Grant or award | 8.0K | $0.00 | — | SEC | |
| SATO VICKI L | Director | S — Open-market sale | 22.0K | $10.05 | $221K | SEC | |
| De Backer Marianne | President and CEO | J — Other acquisition / disposition | 233.5K | $0.00 | — | SEC | |
| De Backer Marianne | President and CEO | J — Other acquisition / disposition | 233.5K | $0.00 | — | SEC | |
| De Backer Marianne | President and CEO | S — Open-market sale [10b5-1] | 72.6K | $9.16 | $664K | SEC | |
| SATO VICKI L | Director | S — Open-market sale [10b5-1] | 22.0K | $9.07 | $200K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Vir Biotechnology, Inc. (VIR). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Coughlin Timothy | 4 | — |
| Napolitano Janet | 3 | $30K |
| BISCHOFBERGER NORBERT W | 2 | — |
| MORE ROBERT J | 2 | — |
| Hatfield Jeffrey S. | 2 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in VIR insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live VIR dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.